Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

February 28, 2010

Conditions
Painful Diabetic Neuropathy
Interventions
DRUG

Placebo Gel

TID x 12 weeks

DRUG

Clonidine Topical Gel (ARC-4558)

TID x 12 weeks

Trial Locations (16)

14642

University of Rochester Medical Center, Rochester

23510

Strelitz Diabetes Institute, Eastern Virginia Medical School, Norfolk

27103

The Center for Clinical Research, Winston-Salem

29576

Waccamaw Pain Partners/Crescent Moon Research, Murrells Inlet

33401

Metabolic Research Institute, West Palm Beach

35294

University of Alabama at Birmingham, School of Medicine, Birmingham

40503

Pain Treatment Center of the Bluegrass, Lexington

44195

Cleveland Clinic, Cleveland

68131

The Creighton Diabetes Center, Omaha

70112

Tulane University Health Sciences Center, New Orleans

77030

The Nerve and Muscle Center of Texas, Houston

78229

Diabetes and Glandular Disease Center, San Antonio

90404

Neurological Research Institute, Santa Monica

95821

Northern California Research, Sacramento

98104

Swedish Pain Center, Seattle

01655

University of Massachuetts Medical School, Division of Diabetes- Clinical Research Office, Worcester

Sponsors
All Listed Sponsors
lead

Arcion Therapeutics Inc

INDUSTRY

NCT00695565 - Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy | Biotech Hunter | Biotech Hunter